L-leucine administration has no effect on mTOR but dampens the p53 activity in hematopoietic progenitors. (A) Flow cytometric quantification of phospho-Rps6 (Ser235/236) and phospho-4E-BP1 (Thr37/46) in myeloid progenitors (CD11b+c-Kit+), proerythroblasts (Ter119lowc-Kit+CD11b−), and mature erythroid precursors (Ter119+CD11b−c-Kit−) on day 14 (n = 6, 3, 5, and 7 for control, control + L-leucine, [D/D], and [D/D] + L-leucine, respectively). Mean fluorescence intensity relative to that of isotype control is presented. (B) p53 transcriptional targets were quantified using real-time PCR in preCFU-E/CFU-E and preGM/GMP populations sorted from individual mice on day 14 (n = 5, 13, and 13 for control, [D/D], and [D/D] + L-leucine, respectively). Error bars represent SD.